CompletedPhase 2NCT01788631

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Studying Sickle cell anemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
David Nathan, MD
Dana-Farber Cancer Institute
Intervention
Regadenoson(drug)
Enrollment
100 enrolled
Eligibility
10-70 years · All sexes
Timeline
2013 – 2016

Study locations (12)

Collaborators

Brigham and Women's Hospital · Boston Children's Hospital · La Jolla Institute for Allergy & Immunology · National Heart, Lung, and Blood Institute (NHLBI) · Washington University School of Medicine · Children's Hospital Medical Center, Cincinnati · University of Illinois at Chicago · Medical College of Wisconsin · Duke University · Johns Hopkins University · Wayne State University · Baylor College of Medicine · UCSF Benioff Children's Hospital Oakland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01788631 on ClinicalTrials.gov

Other trials for Sickle cell anemia

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell anemia →

← Back to all trials